Health Canada's Peptides Crackdown

How Canada's health regulator has moved against online and storefront sellers of unauthorized peptides, and what that record means for anyone in the trade. Research current to 16 October 2026. This note reports public records. It does not give preparation steps, quantities to apply, or an effect in people or animals.

A market that grew too visible

Peptides such as BPC-157, TB-500 and retatrutide are widely promoted online with consumer-outcome language. Over the past three years Health Canada has responded with seizures, public advisories that name sellers, border cooperation and, most recently, a court injunction.

Health Canada's position is explicit. Its 9 April 2026 advisory states that in Canada peptides are generally regulated as prescription drugs and that unauthorized drug products are illegal in Canada. It also addresses the trade's most common label line: a research-use-only statement does not make a product legal or exempt from regulatory requirements (Health Canada, RA-81874). Health Canada's bodybuilding-products page lists semaglutide, tirzepatide, retatrutide, BPC-157, TB-500, GHK-Cu and others as names under which injectable peptides are often sold illegally (Using bodybuilding products).

This note reviews who has been named, what Health Canada did, how sellers responded where that was reported, the law behind the enforcement, and the commercial consequences.

The legal framework in brief

What counts as a drug. Under section 2 of the Food and Drugs Act, a drug includes any substance manufactured, sold or represented for use in diagnosing, treating, mitigating or preventing disease, or in restoring, correcting or modifying organic functions in human beings or animals (Food and Drugs Act). Because the definition turns partly on how a product is represented, marketing matters as much as chemistry.

Market authorization. Under section C.01.014 of the Food and Drug Regulations, no manufacturer shall sell a drug unless a drug identification number has been assigned (C.01.014). Health Canada points readers to the eight-digit DIN as the mark of an authorized drug.

Prescription status. In 2013, Schedule F was repealed and replaced by the Prescription Drug List. The amending regulations bar selling a prescription drug except under a prescription or to specified professionals and businesses (C.01.041 and C.01.043). They limit public advertising of prescription drugs to the brand name, the proper name, the common name, and the price and quantity (C.01.044), and they restrict who may import them (C.01.045) (SOR/2013-122).

Advertising: sections 3 and 9. Section 3 of the Act bars advertising a drug to the general public as a treatment, preventative or cure for the conditions listed in Schedule A.1. Section 9(1) bars labelling, selling or advertising a drug in a way that is false, misleading or deceptive about its character, value, quantity, composition, merit or safety (Food and Drugs Act).

Retailers are covered too. Health Canada's enforcement policy (version 10, 15 September 2026) says that retailers can only sell health products that Health Canada has authorized for sale, whether through online platforms or in a physical location in Canada (POL-0001 v10).

A September 2026 bulletin from the law firm Gowling WLG notes that a research-use-only line does not necessarily change a product's regulatory status, because Health Canada can assess the totality of a product's presentation and marketing. It adds that a substance does not have to be a controlled substance to be illegal to sell (Gowling WLG via Legal 500).

The enforcement record: named sellers

The cases below come from Health Canada's Recalls and Safety Alerts database and departmental statements. Each was checked for this note, but the list may not be complete.

Canlab Research (Québec)

In December 2023, Health Canada warned consumers against injectable products promoted as peptides on Canlab Research websites, including canlabresearch.com and canlab.net. It said it has ordered Canlab Research to stop advertising and selling all unauthorized health products (RA-74731). On 29 July 2026, the department announced that the Superior Court of Québec had granted it a permanent injunction on 11 June 2026. According to Health Canada, Canlab Research had kept selling despite repeated enforcement actions, including a ministerial order. Under the injunction, Canlab and its representatives may not manufacture, test, distribute, sell or advertise unauthorized injectable peptides, or help others do so, including through any website or social media platform accessible with a Canadian Internet Protocol address. Health Canada said non-compliance could lead to referring the matter for prosecution or filing an application for contempt (Health Canada statement; CBC News). The law firm Smart and Biggar reports that Health Canada obtained earlier provisional (2024) and interlocutory (2025) injunctions under section 21.5 of the Act (Mondaq). Health Canada's statement does not mention those orders. No public response from Canlab was found.

Quad (Beloeil, QC)

In June 2024, Health Canada seized injectable peptides and bodybuilding drugs from Quad, which was linked to quadragen.io and advancedresearch.bio. The department reported that, at Health Canada's request, Quad stopped advertising and selling unauthorized health products, including taking down its Quadragen and Advanced Research websites (RA-75741).

Optimum Wellness Centre (Calgary, AB)

In April 2025, Health Canada reported seizing 26 unauthorized injectable peptide products from the clinic, including BPC-157, CJC-1295, ipamorelin and TB-500 (RA-77218). No response from the clinic was reported.

Prime Research (Sherbrooke, QC)

On 14 April 2025, Health Canada reported seizing injectable peptides sold online by Prime Research. Prime Research stopped selling and took down its website at Health Canada's request (RA-77275).

Canada Peptide

On 1 August 2025, Health Canada warned about seized peptide drugs that were being sold via the seller's website. It listed 42 products, including BPC-157, retatrutide, tirzepatide and TB-500, and stated that selling unauthorized drugs is illegal in Canada (RA-77807). The advisory gives no address or web domain, so readers should not assume that any particular website is the business named.

Rize Fitness (Vancouver, BC)

On 24 December 2025, Health Canada reported seizing products labelled PHX Labs from Rize Fitness at 188 Smithe Street, including semaglutide, retatrutide, BPC-157 and TB-500, along with testosterone and DHEA. The products were also sold through phxlab.net. Rize Fitness stopped selling and took down its website at Health Canada's request (RA-81403). CP24 reported that the business did not respond to a request for comment (CP24).

Maxximus Supplements and Cutting Edge Nutrition (Maple Ridge, BC)

The same day, Health Canada reported seizures at two supplement stores. The seized items included injectable peptides under labels such as True North, North Star and CRP Canadian Research Peptides, alongside steroids and SARMs. Some products carried falsified Drug Identification Numbers (RA-81404; Global News). No response from either store was found.

Xenex Laboratories (Coquitlam, BC)

In May 2026, Health Canada published a Type I recall of specific lots of GHK-Cu and BPC-157 powder, naming Xenex Laboratories. The stated reason was that the products sold are unauthorized active pharmaceutical ingredients, and the recall extended to compounding and community pharmacies (RA-82047). Health Canada's Health Product InfoWatch also tracks these actions. Its May 2026 issue lists an advisory on unauthorized injectable peptide drugs (InfoWatch, May 2026).

GLP-1 products

In January 2026, Health Canada said it has identified various retailers in Canada selling unauthorized GLP-1 products, some of them misusing Health Canada logos. It said it is taking action such as seizures and compliance or warning letters (RA-81518). On 13 August 2026, Eli Lilly Canada said that retatrutide has not yet been approved by Health Canada or any other regulatory agency in the world and that Lilly Canada is working with Health Canada and Canadian law enforcement (Lilly Canada).

The border

Health Canada says it is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country (RA-81874). It warns that unauthorized products bought online may be refused entry or seized at the border (Using bodybuilding products). Its enforcement policy lists recommending refusal or seizure to the Canada Border Services Agency, and ordering the removal or destruction of imports at the border, among its tools (POL-0001 v10). No public record was found of a Canada Border Services Agency seizure tied to a specific named Canadian peptide store.

What the media found

In April 2026, CBC News bought three peptide products online. They arrived as powder labelled for research purposes only. Health Canada told CBC it had received four complaints in six months about adverse reactions, though it said a causal link had not been established (CBC News, 18 April 2026). In July 2026, a CBC investigation found doctors prescribing compounded BPC-157. After CBC's questions, Health Canada said it was investigating whether the clinics' advertising complied with the Act (CBC News, 24 July 2026).

Penalties and powers

Criminal offences. Section 31.2 of the Food and Drugs Act applies to contraventions involving a therapeutic product, explicitly including section 3. On indictment, it carries a fine of up to $5,000,000, imprisonment for up to two years, or both. On summary conviction, the maximum is $250,000 and six months for a first offence, and $500,000 and 18 months for a subsequent offence. Under section 31.4, a person who knowingly or recklessly causes a serious risk of injury to human health faces a fine at the court's discretion and up to five years on indictment. On summary conviction, the maximum is $500,000 and 18 months for a first offence and $1,000,000 and two years for a subsequent one (Food and Drugs Act). Health Canada describes the section 31 and 31.2 offences as strict liability offences, which means an accused can raise a defence of due diligence demonstrating that reasonable steps were taken. It may refer cases to the Public Prosecution Service of Canada (POL-0001 v10).

Vanessa's Law and Bill C-47. Vanessa's Law took effect for drugs and medical devices on 6 November 2014. Bill C-47 extended its authorities to natural health products on 22 June 2023 (Vanessa's Law guide). The powers include orders requiring information, label changes and mandatory recalls, as well as the higher fines described above. Breaching such an order is itself a criminal offence. The Minister may also seek a court injunction under section 21.5, the tool reported in the Canlab case. Bill C-47 matters mainly for products sold as natural health products, and Health Canada told CBC that BPC-157 is not approved in any natural health product (CBC News).

Administrative monetary penalties. The consolidated Food and Drugs Act reviewed for this note contains no administrative monetary penalty scheme, and Health Canada's enforcement policy does not list them among its tools for health products (Food and Drugs Act; POL-0001 v10).

What has actually been imposed. None of the peptide advisories or statements reviewed reports a fine, criminal charge or conviction against a peptide seller. To date, the documented outcomes are seizures, public naming, website takedowns made at Health Canada's request, a ministerial order and a permanent court injunction.

Payment processors, platforms and advertising

The commercial consequences can arrive faster than any court case. Stripe prohibits incorrectly labelled research chemicals and any products in violation of law where a business is located or targeted. It also lists card-not-present prescription-only products and pharmaceuticals as restricted (Stripe). Google Ads bars offering prescription drugs without a prescription and suspends violating accounts upon detection and without prior warning. It also bars promoting products that have been subject to any government or regulatory action or warning (Google Ads). Shopify says merchants cannot use Shopify for anything illegal where they do business (Shopify). Lilly Canada says it is calling on platforms, credit card companies, payment processors and shipping carriers to help stop illegal retatrutide sales (Lilly Canada).

No publicly documented case was found of a named Canadian peptide seller being dropped by a specific payment processor, domain registrar or ad platform. The policies show that the risk exists. They do not show how often it has been acted on.

How and why sellers get shut down

Across the cases, the pattern is consistent. Health Canada detects sellers by monitoring online retailers, advertisements, complaints and shipments (POL-0001 v10). It then seizes products and asks the seller to stop. Quad, Prime Research and Rize Fitness responded by taking their websites down. A public advisory names the business and remains searchable. Where selling continued, as with Canlab, Health Canada escalated to a ministerial order and then court injunctions, with prosecution or contempt held in reserve (Canlab statement).

The cases share common features: products without a DIN, injectable formats, and marketing that implies a personal use, sometimes with falsified DINs or misused Health Canada logos (RA-81404; RA-81518). Health Canada's policy says it weighs a party's cooperation and responsiveness and its compliance history when choosing a response (POL-0001, 2018).

Cosmetic peptides and blends

Several peptides on Health Canada's enforcement lists also appear on skincare labels, and many sellers offer vitamin blends or multi-peptide blends. Here, form, route and presentation matter more than the molecule.

Topical cosmetic peptides

The Food and Drugs Act defines a cosmetic as a substance manufactured, sold or represented for use in cleansing, improving or altering the complexion, skin, hair or teeth (Food and Drugs Act). Topical products such as GHK-Cu, Matrixyl-type palmitoyl peptide or argireline creams fall under the Cosmetic Regulations when they meet that definition. Manufacturers and importers must file a Cosmetic Notification Form within 10 days of first sale, listing each ingredient and its concentration. Under section 15.3, a cosmetic cannot be sold after that 10-day window if the notification has not been made. A manufacturer claiming that a cosmetic can influence the chemistry of the skin must hold evidence that validates the claim (section 21) (Cosmetic Regulations). Health Canada stresses that a notification does not constitute approval for sale, nor agreement that the product is classified as a cosmetic (Notification of Cosmetics).

The Cosmetic Ingredient Hotlist is Health Canada's administrative list of prohibited and restricted cosmetic ingredients. A review of the 2025 tables for this note found no entry for GHK-Cu, copper peptides, palmitoyl peptides or acetyl hexapeptides such as argireline (Hotlist). That absence is not an approval. Health Canada says the Hotlist is not exhaustive and that it can act regardless of whether a substance is included, under section 16 of the Act, which bars selling a cosmetic that may injure the user (Hotlist overview).

Where a cosmetic becomes a drug

Health Canada's cosmetic-drug interface guidance weighs three factors: representation, composition and level of action. Products making therapeutic claims are evaluated as drugs, and products claiming effects comparable to cosmetic surgical procedures or drugs would be considered therapeutic. That matters for marketing that likens a topical peptide to an injectable wrinkle product. A cosmetic must exhibit a lack of percutaneous absorption, and products given by a route that punctures the skin, with the sole exception of tattoo ink, are not considered cosmetics (Interface guidance). A later Health Canada notice on topical exosome products added that directions for microneedling or a puncturing route are not consistent with cosmetics (Exosome notice). Ingredients matter too. In 2023, Health Canada recalled a multi-peptide lash serum sold by Linger Beauty because it contained undeclared bimatoprost, a prostaglandin analogue on the Hotlist's prohibited list, and had no DIN (RA-74164).

Vitamin blends and beauty drips

Vitamin B12 and amino acids appear in Schedule 1 of the Natural Health Products Regulations. Schedule 2 excludes a substance that is administered by puncturing the dermis, so that format cannot be licensed as a natural health product with an NPN (NHPR). It is a drug that needs a DIN (C.01.014). Prescription status is a separate question. Plain cyanocobalamin, glutathione and NAD+ are not listed on the federal Prescription Drug List. The list covers only vitamin B12 with intrinsic factor concentrate, and hydroxocobalamin when recommended as an antidote for cyanide poisoning (Prescription Drug List). Authorized cyanocobalamin products of that format carry DINs and are scheduled as Ethical (Drug Product Database). Health Canada defines this category as drugs that do not require a federal prescription but that are generally prescribed by a medical practitioner (DPD terminology). Provinces may add their own restrictions (Prescription Drug List overview). A Drug Product Database search for this note found no glutathione product authorized in that format, only eye irrigation solutions (DPD query). Being off the Prescription Drug List does not make an unauthorized vial legal: without a DIN, it is an unauthorized drug.

Enforcement reflects this. In 2021, Health Canada warned about vitamin, amino-acid, MIC and Myers products that Galena Pharm, a Burnaby pharmacy, supplied to clinics. Its reduced glutathione product was recalled after reports of endotoxin poisoning, and the pharmacy had no drug establishment licence (RA-75003). In September 2025, Health Canada published a recall of Skycare Compounding Laboratories products sold without market authorization. The products included Glut Glow, NAD+, MethylB12Pro and ShapeUp, a vitamin, choline, inositol and methionine blend (RA-78029). In August 2026, it seized unauthorized products described as used for cosmetic purposes from a Hamilton beauty lounge. The seized items included an ascorbic acid product and a Lemon bottle product labelled for topical use but containing vials (RA-82484). Its April 2026 advisory lists NAD+ alongside GHK-Cu among unauthorized injectable products (RA-81874).

Multi-peptide blends

The Rize Fitness seizure listed PHX Labs Glow 70 mg (BPC 10 mg, TB-500 10 mg, GHK-Cu 50 mg) and Klow 80 mg, which adds KPV, as injectable peptide drugs (RA-81403). GHK-Cu also appears in the Canada Peptide and Optimum Wellness Centre lists, and the Canada Peptide list includes Pal-GHK (RA-77807; RA-77218). Because a DIN identifies a product's specific active ingredients and strengths (DPD terminology), blending unauthorized peptides does not create an authorized product.

Why the Xenex recall covered GHK-Cu

The Xenex notice is brief. It covers 5 g and 50 g powders of GHK-Cu and BPC-157 that were distributed to compounding and community pharmacies and recalled as Type I because they are unauthorized active pharmaceutical ingredients (RA-82047). It gives no further explanation. Health Canada's compounding policy says compounded products should be produced from an authorized drug or an active pharmaceutical ingredient used in an authorized drug for use in Canada or listed in a recognized pharmacopoeia (POL-0051). In the context of GLP-1 drugs, Health Canada has described compounding with unauthorized ingredients as a form of manufacturing (College of Pharmacists of British Columbia). The Drug Product Database search for this note found no authorized product containing GHK-Cu or BPC-157. These points fit the recall, but the notice does not cite them. It is also unclear how Health Canada would treat cosmetic-grade GHK-Cu sold to cosmetic formulators rather than pharmacies. No public guidance on that question was found.

The practical line. A copper-peptide cream may fall under the cosmetic framework if it is sold with appearance-only claims, has been notified, and contains no prohibited ingredients. A lyophilized GHK-Cu vial, a Glow blend, or a B12, glutathione or NAD+ product in vial form is neither a cosmetic nor a natural health product. Without a DIN, it is an unauthorized drug, whatever its label says.

Practical compliance takeaways for sellers

These points summarize what the public record shows. They are not legal advice.

• Do not rely on a research-use-only label. Health Canada has said in writing that this labelling does not make products legal or exempt them from the rules (RA-81874). Regulators can look at the whole presentation of a product (Gowling WLG via Legal 500).
• Audit every claim and image. Outcome language, testimonials and influencer content can establish that a product is represented for use as a drug, and can trigger sections 3 and 9 (Food and Drugs Act).
• Know the status of each compound. Some peptides, such as semaglutide and tirzepatide, are authorized prescription drugs available only through pharmacies with a prescription. Others, such as retatrutide, are not approved anywhere (RA-81518; Lilly Canada).
• Check importation rules. The Food and Drug Regulations restrict who may import prescription drugs (SOR/2013-122), and Health Canada flags non-compliant shipments to the Canada Border Services Agency.
• Keep records showing due diligence. Because the main offences are strict liability, documented reasonable steps can matter (POL-0001 v10).
• Respond promptly to regulators. Obstructing an inspector or giving false information is an offence (POL-0001 v10). In the public record, continued sales after an order led to an injunction.
• Read vendor terms. Payment, e-commerce and ad platforms set their own rules, and those rules can end a business faster than a regulator can (Stripe; Google Ads; Shopify).

A note on legal advice

This note is general information based on public sources. It is not legal advice. The regulatory status of a peptide depends on its form, intended use, labelling and marketing. Any business making, importing, advertising or selling peptides in Canada should consult a lawyer experienced in Canadian food and drug regulation before acting on anything here.

Sources

1. Health Canada, RA-81874, 9 April 2026
2. Health Canada, Using bodybuilding products
3. Health Canada, Canlab Research permanent injunction statement, 29 July 2026
4. Health Canada, Canlab Research advisory, RA-74731, 13 December 2023
5. Health Canada, Quadragen and Advanced Research, RA-75741, 26 June 2024
6. Health Canada, Optimum Wellness Centre, RA-77218, 1 April 2025
7. Health Canada, Prime Research, RA-77275, 14 April 2025
8. Health Canada, Canada Peptide, RA-77807, 1 August 2025
9. Health Canada, Rize Fitness, RA-81403, 24 December 2025
10. Health Canada, Maple Ridge stores, RA-81404, 24 December 2025
11. Health Canada, GHK-Cu and BPC-157 powder recall, RA-82047, 7 May 2026
12. Health Canada, GLP-1 advisory, RA-81518, 21 January 2026
13. Health Canada, Health Product InfoWatch, May 2026
14. Food and Drugs Act, R.S.C. 1985, c. F-27
15. Food and Drug Regulations, section C.01.014
16. Canada Gazette Part II, SOR/2013-122
17. Health Canada, POL-0001 version 10, 15 September 2026 (PDF)
18. Health Canada, POL-0001 overview page
19. Health Canada, POL-0001 (2018 version, superseded)
20. Health Canada, Guide to authorities under Vanessa's Law, August 2023
21. CBC News, 18 April 2026
22. CBC News, 24 July 2026
23. CBC News, 31 July 2026
24. CP24, 24 December 2025
25. The Canadian Press via Global News, 24 December 2025
26. Smart and Biggar via Mondaq, 26 August 2026
27. Gowling WLG via Legal 500, 17 September 2026
28. Eli Lilly Canada, 13 August 2026
29. Stripe, Prohibited and Restricted Businesses
30. Google Ads, Healthcare and medicines
31. Shopify, Acceptable Use Policy
32. Cosmetic Regulations, C.R.C., c. 869
33. Health Canada, Notification of Cosmetics
34. Health Canada, Cosmetic Ingredient Hotlist overview
35. Health Canada, Cosmetic Ingredient Hotlist
36. Health Canada, cosmetic-drug interface guidance
37. Health Canada, topical exosome classification notice
38. Health Canada, Multi-Peptide Lash Serum recall, RA-74164, 21 August 2023
39. Natural Health Products Regulations, SOR/2003-196
40. Health Canada, Prescription Drug List overview
41. Health Canada, Prescription Drug List
42. Health Canada, Drug Product Database, cyanocobalamin injection, DIN 02530643
43. Health Canada, Drug Product Database terminology
44. Health Canada, Drug Product Database query for glutathione, 16 October 2026
45. Health Canada, Galena Pharm advisory, RA-75003, 12 February 2021
46. Health Canada, Skycare Compounding Laboratories recall, RA-78029, 4 September 2025
47. Health Canada, Dyosa Beauty and Wellness Lounge advisory, RA-82484, 12 August 2026
48. Health Canada, POL-0051, 26 January 2009
49. College of Pharmacists of British Columbia, Health Canada position on unauthorized GLP-1 manufacturing

This regulatory summary does not offer products. Listed materials are on the research catalogue. Other notes are on the research blog, and the full set of those notes is the blog index.